This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RGS9 / Regulator of G-protein signaling 9 · Western blot design guide
Design a Western Blot for RGS9
Source-linked RGS9 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RGS9 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
RGS9 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~77 kDa | |
| Observed band | ~77 kDa | |
| Gel | 5–20% (catalog A04748-1) | |
| Positive control | Retina (IHC candidate; verify WB) +1 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 5 isoform(s) |
Section 1
Source-Linked RGS9 Western Blot Protocol Options
The A04748-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human SH-SY5Y, human U20S, human HEL, human Daudi (catalog A04748-1) |
| Gel % | 5–20% (catalog A04748-1) |
| Load | 30 ug; reducing conditions (catalog A04748-1) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog A04748-1) |
| Membrane | nitrocellulose membrane (catalog A04748-1) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog A04748-1) |
| Primary antibody | A04748-1 · 0.5 μg/mL (catalog A04748-1) |
| Primary incubation | overnight at 4°C (catalog A04748-1) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog A04748-1) |
| Secondary incubation | 1.5 hour at RT (catalog A04748-1) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog A04748-1) |
| Detection | ECL (catalog A04748-1) |
Section 2
What Is the Expected RGS9 Western Blot Band Size?
RGS9 is predicted at 77 kDa and observed at approximately 77 kDa; splice isoforms may affect migration, but distinct band sizes are unestablished.
| Band near 77 kDa | Matches the reported RGS9 band in reducing whole-cell blots. |
| Several bands at different positions | Could reflect RGS9 isoforms if they are expressed and resolve separately; band identity needs confirmation. |
| Weak band in soluble fraction | Isoform 3 may be underrepresented because it is targeted to membranes through RGS9BP. |
| Band enriched in membrane fraction | Consistent with the reported membrane location of isoform 3; confirm RGS9 identity. |
💡Expected RGS9 appearanceUniProt predicts 77 kDa, and antibody QC reports a band at approximately 77 kDa in reducing whole-cell lysates; confirm identity with an appropriate RGS9 control.
| UniProt predicted mass | The 77 kDa reference agrees with the reported approximately 77 kDa band. |
| Isoforms 1 and 2 | These named splice isoforms have no supplied individual masses or demonstrated migration difference. |
| Isoform 3 | This named splice isoform has no supplied individual mass or demonstrated migration difference. |
| Isoforms 4 and 5 | These named splice isoforms have no supplied individual masses or demonstrated migration difference. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Membrane-associated isoform 3 may be poorly recovered during extraction. | Check the membrane fraction and verify RGS9 detection with a positive control. |
| Band higher than expected | The band's identity is uncertain; no listed feature establishes an upward shift. | Compare with the approximately 77 kDa band and test an RGS9 depletion control. |
| Band lower than expected | An alternative isoform or degradation is possible, but neither size is established. | Use fresh lysate and confirm identity with RGS9 depletion or an independent antibody. |
| Multiple bands | Five named splice isoforms may contribute if expressed and separable. | Check isoform expression and confirm each band's identity with an RGS9 control. |
| Weak or no signal | Membrane-targeted isoform 3 may be poorly represented in the tested fraction. | Check extraction and compare whole-cell and membrane fractions with a positive control. |
Experiment evidence
Western blot images showing RGS9 band
A04748-1 · RGS9
PA2241 · RGS9
PA2241 · RGS9
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RGS9 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for RGS9 in Western blot, you can use retina tissue, which has high HPA expression.
Positive control: Retina (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: Retina is a strong positive candidate, but membrane-associated isoform 3 may require a membrane-containing lysate.
HPA tissue expression evidence for RGS9
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Retina | photoreceptor cells | High | Protein (IHC) | HPA → |
| Rectum | mucosal lymphoid cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced RGS9 Western Blot Tips
Deeper troubleshooting and optimisation questions for RGS9, answered from its protein features.
How should RGS9 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Which RGS9 isoforms could produce different bands?
Isoforms · Five isoforms are listed. Relative to the 674-residue canonical sequence, isoform 2 lacks residues 470–674, isoform 4 lacks 1–229, and isoform 3 lacks 216–218 and 488–674 and replaces 470–487. Isoform 5 lacks 216–218. These sequence differences could affect band positions, but the features do not establish visible bands.
Can phosphorylation explain an unexpected RGS9 band?
PTM · RGS9 has a phosphoprotein keyword, but the supplied features give no modified residue coordinates. That keyword alone does not establish a visible shift or identify an unexpected band as phosphorylated RGS9.
Does this guide establish induction of RGS9?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for RGS9?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A04748-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should RGS9 bands be quantified across samples?
Quantitation · Define which isoform or bands the antibody measures before comparing samples. Several isoforms have substantial sequence differences, so a single band may not represent total RGS9. Apply the same band selection across samples and report it.
Should RGS9 run above its predicted mass?
Interpretation · The predicted mass and observed band are both approximately 77 kDa. The supplied features do not establish a mass shift; confirm any different band before assigning a cause.
Check the antibody’s binding region against the isoform sequences. A region within canonical residues 470–674 is absent from isoform 2, while residues 1–229 are absent from isoform 4. Use UniProt canonical coordinates when comparing regions; antibody numbering may differ.
Isoform 3 is listed as a peripheral membrane protein targeted through interaction with RGS9BP. Consider which sample fraction was loaded when interpreting its detection. The supplied features do not establish the localization of every isoform.
RGS9 forms a heterodimer with GNB5, but that interaction alone does not identify an unexpected Western blot band. Check the band against the expected RGS9 size, the listed isoform sequences, and the antibody’s binding region.
Check the antibody’s binding region against the isoform sequences. A region within canonical residues 470–674 is absent from isoform 2, while residues 1–229 are absent from isoform 4. Use UniProt canonical coordinates when comparing regions; antibody numbering may differ.
Isoform 3 is listed as a peripheral membrane protein targeted through interaction with RGS9BP. Consider which sample fraction was loaded when interpreting its detection. The supplied features do not establish the localization of every isoform.
RGS9 forms a heterodimer with GNB5, but that interaction alone does not identify an unexpected Western blot band. Check the band against the expected RGS9 size, the listed isoform sequences, and the antibody’s binding region.
Boster reagents
RGS9 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-RGS9 Antibody Picoband®
Cat # A04748-1
Real WB data
Anti-RGS9 Antibody Picoband®
Cat # PA2241
Two anti-RGS9 antibodies have WB images: A04748-1 shows a band near the expected 77 kDa in four human cell lysates; PA2241 shows rat and mouse brain tissue lysates. These images document the stated samples, not broader validation.
Which to pick: For human cell lysates, choose A04748-1, which lists human reactivity and shows four tested cell lines. For rat or mouse brain lysates, choose PA2241, whose WB image uses those tissues; it also lists human reactivity, without a human sample shown.
Source: BosterBio RGS9 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry O75916.
- Human Protein Atlas. RGS9 tissue expression.
- PMC3963927 — target-verified WB comparison
- PMC2890236 — target-verified WB comparison
- PMC4459754 — target-verified WB comparison